technology · stock-sale · portfolio-rebalancing
Government Operations Chair Pete Sessions Sells Alphabet Stock in Rare Trade
The Texas Republican, who trades only a few times a year, quickly disclosed a sale of up to $50,000 of the tech giant's shares.
2026-09-22 — Pete Sessions · GOOGL
Key facts
- Rep. Pete Sessions sold between $15,001 and $50,000 of Alphabet stock on September 14, 2026.
- The trade was disclosed just four days later, well ahead of the 45-day STOCK Act deadline.
- Sessions is a highly infrequent trader, having executed only four transactions in the past year.
- On the same day, Sessions sold an identical amount of AbbVie stock, suggesting a portfolio-wide rebalancing.
Rep. Pete Sessions (R-Tex.) is not known for frequenting the stock market. Over the past year, the House veteran has disclosed just four financial transactions, preferring a highly selective, low-churn approach to his personal portfolio.
That made it notable when Sessions executed a sale of Alphabet Inc. (GOOGL) stock valued between $15,001 and $50,000 on September 14, 2026. What was even more unusual was the speed of his disclosure: Sessions filed the transaction report just four days later, on September 18. Under the STOCK Act, members of Congress are required to disclose their financial transactions within 45 days, and these transactions are reported in ranges rather than exact dollar amounts.
Our analysis scored the transaction a 42/100, reflecting its low regulatory overlap but highly unusual timing for this member. Sessions serves as the Chair of the Subcommittee on Government Operations under the Committee on Oversight and Government Reform. While the subcommittee oversees federal IT procurement, it has no direct regulatory authority over Alphabet’s core advertising or antitrust issues.
The sale occurred against a backdrop of broader regulatory and legal challenges for the tech giant. A Congressional Research Service report highlights the Department of Justice’s ongoing ad tech antitrust litigation against Google. Additionally, on the very day Sessions filed his disclosure, the International Trade Commission published a notice instituting a patent investigation involving Google LLC, stemming from a complaint filed in August.
However, the transaction may simply point to routine portfolio rebalancing rather than regulatory anxiety. On the same day as his Alphabet sale, Sessions executed an identical sale of pharmaceutical giant AbbVie (ABBV) in the exact same range of $15,001 to $50,000. Prior to this, Sessions had not touched Alphabet stock since 2017.
Sessions is not the only lawmaker trimming exposure to the company. Rep. Thomas H. Kean Jr. (R-N.J.) has also been a steady seller, divesting roughly $89,000 in Alphabet shares over several transactions.
For an infrequent trader like Sessions, a quick exit can look like a signal—but a matching pharmaceutical sale suggests a simple housecleaning of the portfolio.